Skip to main content

Peer Review reports

From: Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution

Original Submission
12 Jul 2018 Submitted Original manuscript
17 Jul 2018 Author responded Author comments - Nuno Cerveira
Resubmission - Version 2
17 Jul 2018 Submitted Manuscript version 2
7 Sep 2018 Reviewed Reviewer Report - Anna Turkina
7 Sep 2018 Reviewed Reviewer Report - Edgar Faber
10 Sep 2018 Reviewed Reviewer Report - David Yeung
10 Oct 2018 Author responded Author comments - Nuno Cerveira
Resubmission - Version 3
10 Oct 2018 Submitted Manuscript version 3
9 Nov 2018 Reviewed Reviewer Report - Edgar Faber
25 Nov 2018 Reviewed Reviewer Report - David Yeung
30 Nov 2018 Author responded Author comments - Nuno Cerveira
Resubmission - Version 4
30 Nov 2018 Submitted Manuscript version 4
Publishing
30 Nov 2018 Editorially accepted
12 Dec 2018 Article published 10.1186/s12885-018-5167-y

You can find further information about peer review here.

Back to article page